Skip to main content

Terlipressin Side Effects

Medically reviewed by Drugs.com. Last updated on Apr 18, 2023.

Applies to terlipressin: intravenous powder for solution.

Warning

Intravenous route (Powder for Solution)

Warning: Serious Or Fatal Respiratory FailureTerlipressin may cause serious or fatal respiratory failure. Patients with volume overload or with acute-on-chronic liver failure (ACLF) Grade 3 are at increased risk. Assess oxygenation saturation (eg, SpO2) before initiating terlipressin.Do not initiate terlipressin in patients experiencing hypoxia (eg, SpO2 less than 90%) until oxygenation levels improve. Monitor patients for hypoxia using continuous pulse oximetry during treatment and discontinue terlipressin if SpO2 decreases below 90%.

Serious side effects of Terlipressin

Along with its needed effects, terlipressin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking terlipressin:

More common

Less common

Incidence not known

For Healthcare Professionals

Applies to terlipressin: intravenous powder for injection.

Cardiovascular

Common (1% to 10%): Bradycardia, hypertension, hypotension, ischemia, ischemia-related events, vasoconstriction, pallor, supra-ventricular arrhythmia, ventricular arrhythmia

Uncommon (0.1% to 1%): Atrial fibrillation, ventricular extrasystoles, tachycardia, cardiac failure, myocardial infarction, torsade de pointes, cyanosis, hot flushes, chest pain, fluid overload with pulmonary edema, angina pectoris, peripheral cyanosis

Rare (0.01% to 0.1%): Ventricular fibrillation

Very rare (less than 0.01%): Myocardial ischemia[Ref]

Ischemia-related events included skin discoloration, cyanosis, ischemia, and intestinal ischemia.[Ref]

Dermatologic

Common (1% to 10%): Paleness

Uncommon (0.1% to 1%): Skin necrosis unrelated to the site of administration, lymphangitis[Ref]

Gastrointestinal

Very common (10% or more): Abdominal pain (19.5%), nausea (16%), diarrhea (13%)

Common (1% to 10%): Transient abdominal cramps

Uncommon (0.1% to 1%): Vomiting, intestinal ischemia[Ref]

General

-The most common adverse reactions with a frequency of 10% or greater were abdominal pain, nausea, respiratory failure, diarrhea, and dyspnea.

-The most common adverse reactions that led to treatment discontinuation were respiratory failure, abdominal pain, and intestinal ischemia or obstruction.[Ref]

Local

Uncommon (0.1% to 1%): Local cutaneous necrosis[Ref]

Metabolic

Common (1% to 10%): Fluid overload (8.5%)

Uncommon (0.1% to 1%): Hyponatremia

Very rare (less than 0.01%): Hyperglycemia[Ref]

Nervous system

Common (1% to 10%): Headache

Uncommon (0.1% to 1%): Triggering of a convulsive disorder

Very rare (less than 0.01%): Stroke[Ref]

Other

Common (1% to 10%): Sepsis (5.5%)

Uncommon (0.1% to 1%): Uterine hypertonus, uterine ischemia

Frequency not reported: Decreased serum sodium, uterine constriction, decreased uterine blood flow

Postmarketing reports: Gangrene[Ref]

In a clinical study, 67% of the patients developed acute reduction in serum sodium.[Ref]

Renal

Frequency not reported: Decreased serum creatinine[Ref]

Respiratory

Very common (10% or more): Respiratory failure (15.5%), dyspnea (12.5%)

Common (1% to 10%): Pleural effusion (5.5%)

Uncommon (0.1% to 1%): Respiratory distress, pulmonary edema, pain in the chest, bronchospasm[Ref]

References

1. Product Information. Terlivaz (terlipressin). Mallinckrodt Hospital Products Inc. 2022.

2. Product Information. Glypressin (terlipressin). Ferring Pharmaceuticals Pty Ltd. 2020.

3. Product Information. Variquel (terlipressin). Alliance Pharmaceuticals Ltd. 2021.

4. Product Information. Glypressin (terlipressin). Ferring Pharmaceuticals Ltd. 2022.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.